Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

KPTI · Nasdaq

Karyopharm Therapeutics Inc. (KPTI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Karyopharm Therapeutics Inc. in 2026. The next earnings report is expected on October 29, 2026.

Earnings calendar

Next earnings date

29 Oct 2026

In 71 days

EPS estimate

-1.13

Revenue estimate

32.9M

Past earnings

13 Aug 2026
EPS actual
-2.32 (-69.1%)
estimate -1.37
Revenue actual
33.4M (+3.8%)
estimate 32.2M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
14 May 2026
EPS actual
-1.24 (+12.5%)
estimate -1.42
Revenue actual
35.1M (+11.7%)
estimate 31.4M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
11 May 2026
EPS actual
—
estimate -1.42
Revenue actual
—
estimate 31.4M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Feb 2026
EPS actual
-5.71 (-186.3%)
estimate -1.99
Revenue actual
34.1M (-2.9%)
estimate 35.1M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Karyopharm Therapeutics missed consensus on EPS but exceeded revenue expectations in its latest earnings, with EPS of -$2.32 versus an estimate of -$1.3717 and revenue of $33.43 million, 3.8% above estimates. In the prior quarter both EPS and revenue came in ahead of expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Richard A. Paulson
Employees
279
IPO date
06 Nov 2013
ISIN
US48576U2050
Website
karyopharm.com

Frequently asked questions

When does Karyopharm Therapeutics Inc. (KPTI) next report earnings?

Karyopharm Therapeutics Inc. (KPTI) is scheduled to report earnings on October 29, 2026.

What was Karyopharm Therapeutics Inc.'s most recent earnings date?

Karyopharm Therapeutics Inc. (KPTI) last reported earnings on August 13, 2026.

Where is Karyopharm Therapeutics Inc. stock listed?

Karyopharm Therapeutics Inc. (KPTI) is listed on Nasdaq.